DoMore Diagnostics named "AI Startup of the Year"
Oslo - June 5, 2024 - DoMore Diagnostics has been awarded the prestigious title of "AI Startup of the Year" by the Norwegian Artificial Intelligence Research Consortium (NORA) for its pioneering use of artificial intelligence to personalize cancer treatment.
CTO and Co-Founder Sepp De Raedt received the award on behalf of the company at the NORA annual conference held in Kristiansand this week. NORA brings together leading Norwegian universities, research institutions and professionals with the aim to strengthen Norwegian research and education within artificial intelligence, machine learning and robotics. The award recognizes research-driven startup companies that have achieved outstanding results in the development or use of artificial intelligence. In its justification, the jury emphasizes that the company has shown exceptional progress, established international collaborations and secured significant funding, thus strengthening its position as a leader in AI-driven cancer diagnostics.
“We are incredibly proud that NORA recognizes our work to transform diagnostics and treatment for cancer patients. Artificial intelligence opens up great opportunities to increase the quality of cancer treatment, relieve critical resources in the healthcare system, and make a meaningful difference in patients' lives. With increasing early diagnostics, it is becoming even more important to know who benefits from aggressive treatment and who is better off without it," says Torbjørn Furuseth, CEO and Co-Founder of DoMore Diagnostics.”
About NORA
NORA – The Norwegian Artificial Intelligence Research Consortium – aims to strengthen Norwegian research and education within artificial intelligence, machine learning and robotics, as well as other relevant research that supports the development of artificial intelligence applications. NORA shall contribute in developing joint research projects between partners, NORA will take an active part in establishing start-up companies in the artificial intelligence field, as well as strengthening the collaboration between the consortium partners' research communities and the business community.
The consortium will further contribute to positioning Norwegian research in artificial intelligence on the international arena and have a special responsibility for developing activities aimed at Horizon 2020 and Horizon Europe. In addition, the consortium will create meeting places and host various events for researchers and students. The NORA consortium was established 21 November 2018. The consortium is a collaboration between eight Norwegian universities: NMBU, OsloMet, UiA, UiB, UiO, UiS, UiT and USN, five university colleges: BI, HiØ, HINN, HVL and HK and five research institutes: NORCE, Simula, SINTEF, WNRI and Norsk Regnesentral
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefitting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
Photo Credits: Christoffer Hals
For more information, please visit:
The Lancet publication.
The Lancet Oncology publication.
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com